Neuburgh Advisers LLC grew its stake in Orthopediatrics Corp (NASDAQ:KIDS) by 125.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,970 shares of the company’s stock after buying an additional 1,650 shares during the quarter. Neuburgh Advisers LLC’s holdings in Orthopediatrics were worth $116,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in the company. Roubaix Capital LLC bought a new stake in shares of Orthopediatrics in the second quarter worth $3,497,000. Wasatch Advisors Inc. lifted its position in shares of Orthopediatrics by 28.2% in the second quarter. Wasatch Advisors Inc. now owns 347,598 shares of the company’s stock worth $13,556,000 after purchasing an additional 76,534 shares in the last quarter. Calamos Advisors LLC bought a new stake in shares of Orthopediatrics in the second quarter worth $2,373,000. Russell Investments Group Ltd. bought a new stake in shares of Orthopediatrics in the second quarter worth $2,055,000. Finally, Swiss National Bank bought a new stake in shares of Orthopediatrics in the second quarter worth $640,000. 48.16% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently commented on the stock. Zacks Investment Research lowered shares of Orthopediatrics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th. ValuEngine lowered shares of Orthopediatrics from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub raised shares of Orthopediatrics from a “sell” rating to a “hold” rating in a research report on Wednesday, September 4th. Finally, Needham & Company LLC started coverage on shares of Orthopediatrics in a research report on Wednesday, June 19th. They set a “buy” rating and a $53.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $44.25.
Orthopediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.05). Orthopediatrics had a negative return on equity of 12.92% and a negative net margin of 15.77%. The firm had revenue of $18.20 million for the quarter, compared to the consensus estimate of $18.44 million. During the same period last year, the company posted ($0.21) earnings per share. The business’s revenue was up 20.5% compared to the same quarter last year. Analysts predict that Orthopediatrics Corp will post -0.82 EPS for the current fiscal year.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Featured Article: How to start trading in the forex market?
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.